CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 81 enrolled
Drug / intervention
BeShape Onedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05896696
NCT05896696N/ACompleted

Prospective Clinical Study for the Evaluation of the Efficacy and Safety of the BeShape One Device for Non-invasive Waist Circumference Reduction

BeShape Technologies Ltd.·interventional·Posted Jun 9, 2023·Updated Oct 16, 2024

In Brief

A clinical study evaluating BeShape One for Dermatological Non-Disease. Completed, enrolled 81 participants across 2 sites in 2 countries.

Detailed Summary

The goal of this clinical trial is to evaluate the safety and efficacy of the BeShape One device for non-invasive waist circumference reduction in adults between the ages of 18 and 65. The main question\[s\] it aims to answer are: * reduction in waist circumference following treatment with the BeShape One device at the final 6 and 12-week follow-up visits compared to baseline * Subject improvement and satisfaction * Investigator satisfaction * Subject comfort/pain level Participants will undergo a single treatment with the BeShape One device at the Baseline visit and will return for two follow up visits at 6 and 12 weeks post treatment. Researchers will compare the results at the follow up visits to Baseline.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesLithuania, United States
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedJun 9, 2023
Enrollment StartApr 28, 2022
Primary CompletionMar 16, 2023
Study CompletionApr 27, 2023
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 3.1 years ago

Interventions

BeShape Onedevice

Single treatment with the BeShape One device. Participants will receive treatment on at least 4 abdomen/flanks treatment areas and up to 6 treatment areas, at the discretion of the investigator. The subject will receive one treatment on each treatment area.